StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Saturday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The business’s 50-day moving average price is $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The company has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45.
About Nabriva Therapeutics
Read More
- Five stocks we like better than Nabriva Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Insider-Buy Stocks to Add to Your Watchlist Now
- Using the MarketBeat Dividend Yield Calculator
- Commvault Stock: AI Cybersecurity Giant Ready to Double Again
- 3 Small Caps With Big Return Potential
- Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.